09:05 AM EST, 12/16/2024 (MT Newswires) -- Senti Biosciences ( SNTI ) said Monday that the first patient has been dosed in the pilot trial of SN301A to treat hepatocellular carcinoma.

The biotech firm said the trial, which is taking place in mainland China, is part of a collaboration with Celest Therapeutics.

Senti Bio said the two companies have the option to expand clinical development of SN301A to Hong Kong, Macau and Taiwan. It also said it will maintain all development and commercialization rights outside of mainland China, Hong Kong, Macau, and Taiwan.

Price: 5.21, Change: -0.36, Percent Change: -6.46